Radiofrequency (RF) Ablation Prospective Outcomes Study
CompletedNCT04673032
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The objective of this study is to compile real-world outcomes of Boston Scientific commercially approved radiofrequency (RF) ablation systems in the treatment of patients diagnosed with pain
Study details
- Official title
- Radiofrequency (RF) Ablation Prospective Outcomes Study
- Conditions
- Interventions
- Device: Radiofrequency Ablation
- Sponsor
- Boston Scientific Corporation
- Start date
- 2020-12-22
- Primary completion
- 2025-02-07
- Sex
- All
- Age range
- from 0 Years
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- Belgium, Italy, Netherlands, United States
- Total sites listed
- 15
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Key Inclusion Criteria: * Study candidate is scheduled to be treated with a commercially approved Boston Scientific RF system for pain per local Directions for Use (DFU) * Signed a valid, IRB/EC/REB-approved informed consent form Key Exclusion Criteria: * Meets any contraindications per locally applicable Directions for Use (DFU) * Currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain relief or to complete study assessments
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04673032